Journal: Biomolecules

Article Title: Adaptation to Arginine Deprivation Leads to a More Aggressive, Therapy-Resistant Phenotype in HNSCC Cells

doi: 10.3390/biom15060900

Figure Lengend Snippet: SAS-R9 cells are relatively radioresistant. ( A ) Relative cell radiosensitivity was analyzed using a 2-D radiobiological colony forming assay; error bars = SD; ** p < 0.01. ( B ) Representative images of 2-D colonies from one out of four experiments. ( C ) Plating efficacy of sham-irradiated SAS and SAS-R9 cells. Error bars = SD. ( D ) DNA double-stranded breaks (DSBs) were analyzed by γ-H2A.X foci analysis in SAS and SAS-R9 cells 24 h after 4 Gy of X-ray irradiation; * p < 0.05. ( E ) Images show the exemplary SAS and SAS-R9 cells with γ-H2A.X foci24 h after 4 Gy of X-ray irradiation. Scale bars = 10 µm; n.s.—not significant. ( F ) The foci-negative populations of SAS and SAS-R9 cells 24 h after 4 Gy of X-ray irradiation. The foci-negative cells were defined as cells with ≤3 foci per nuclei. ( G ) The RT2 transcriptomic gene sets that are most significantly deregulated in SAS-R9 cells have a similar pattern of changes in FaDu RR cells; ** p < 0.01; *** p < 0.001. ( H ) Our findings suggest that cell selection and reprogramming, which are induced by repeated exposure to ADT, can result in tumor cell resistance to radiotherapy-induced DNA damage.

Article Snippet: Furthermore, a comparative analysis of the transcriptomic profiling in SAS-R9 and HNSCC FaDu RR, which were repeatedly irradiated with 12 fractions of 4 Gy of X-rays and acquired relative radioresistance [ ], revealed that the transcriptomic gene sets that are most significantly deregulated in SAS-R9 cells have a similar pattern of changes in FaDu RR cells ( G).

Techniques: Irradiation, Selection

Journal: Biomolecules

Article Title: Natural Compounds Modulate Drug Transporter Mediated Oral Cancer Treatment

doi: 10.3390/biom10091335

Figure Lengend Snippet: ATP-binding cassette G2 (ABCG2) expression was different in varied head and neck cancer (HNC) cell lines, which affected the amount of protoporphyrin IX (PpIX) and the survival percentage while the cells were treated with 5-aminolevulinic acid photodynamic therapy (ALA-PDT), and was modulated by different compounds. ( A ) Western blot analysis showed that ABCG2 was highly expressed in OECM1 but not in SAS, HSC3, and Fadu cells. ( B ) In parental status, PpIX amount of the four HNC cell lines showed no significant difference. For those cells treated with ALA, OECM1 produced the lowest amount of PpIX in comparison with SAS, HSC3, and Fadu cells. Switch of SAS cells from a medium containing 25 mM glucose to 5.5 mM glucose ( C ) induced ABCG2 expression and ( D ) downregulated PpIX accumulation in a time-dependent manner. ( E ) Western blot analysis for phospho-Akt, total Akt, Nrf2, and ABCG2 protein expression in OECM1 and SASL90d cells with/without treatment of PI3K inhibitor LY294002 ( n ≥ 3; * p < 0.05; *** p < 0.001). IC 50 of ALA-PDT treatment was measured in ABCG2-enriched cells: ( F ) OECM1, parental SAS, and SASL90d cells; ( G ) OECM1; and ( H ) SASL90d. ABCG2 level was significantly inhibited by gefitinib, epigallocatechin gallate (EGCG), and curcumin but not by naringenin. n ≥ 3, * p < 0.05, *** p < 0.001, **** p < 0.0001.

Article Snippet: HNC cell lines, including OECM1, SAS, HSC3, and FaDu, were obtained from the Japanese Collection of Research Bioresources (Tokyo, Japan).

Techniques: Binding Assay, Expressing, Western Blot, Produced, Comparison

Journal: Cancers

Article Title: Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review

doi: 10.3390/cancers13133126

Figure Lengend Snippet: Characteristics of preclinical studies.

Article Snippet: RN927C , Trop-2 , PF-06380101 (AUR0101) an auristatin microtubule inhibitor (a cytotoxic Dolastatin 10 analogue) , Cleavable AcLys-VC-PABC , Breast cancer, colon cancer, HNC, lung cancer, ovarian cancer, pancreatic cancer, skin cancer , HNC cell lines: Fadu , Pfizer/Rinat , Strop 2016 [ ] , .

Techniques: Transfection

Journal: mAbs

Article Title: Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV

doi: 10.1080/19420862.2017.1319023

Figure Lengend Snippet: Inhibition of ligand-dependent and ligand-independent proliferation. (a) Inhibition of proliferation of MCF-7, NCI-N87, and A549 cells incubated for one week under low (0.2%) serum concentrations in the presence of 10 ng/ml heregulin and either IgG 3–43 (3–43) or rituximab (Control) as a negative control antibody. (b) Inhibition of proliferation of FaDu cells without the addition of heregulin under the same conditions as in (a). (c) Colony formation assay. SKBR3 or BT474 were grown in 12-well plates (1,000 cells per well) and incubated with IgG 3–43 (50 nM) or trastuzumab (Tras.) for 12 d. Medium and antibodies were exchanged after 7 d. Cells incubated without antibody were included as a control (con). Shown are crystal violet-stained wells and the quantification of 2 independent experiments performed with triplicate wells.

Article Snippet: FaDu cells (5 × 10 6 ) were injected subcutaneously in the left and right flanks of female SCID beige mice (Charles River).

Techniques: Inhibition, Incubation, Control, Negative Control, Colony Assay, Staining